genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2017
Acceleron Pharma
Cancer
Acceleron Halts Development of Cancer Candidate Dalantercept
GEN Staff Writer
-
June 13, 2017
0
Drug Discovery
Celgene Pays Acceleron $25M to Add Second Candidate to Anemia Collaboration
GEN Staff Writer
-
August 3, 2011
0
News
Shire Pays Acceleron $45M Up Front for Neuromuscular Disease Candidates
GEN Staff Writer
-
September 9, 2010
0
News
Acceleron Goes against the Grain with Expansions
GEN Staff Writer
-
May 1, 2009
0
News
The Biggest R&D Collaboration Spenders in 2008
GEN Staff Writer
-
January 1, 2009
0
Scroll Up
Scroll Up
